German pharmaceutical group Stada is in talks with two private equity firms over a potential sale, according to a report by Welt. 

The discussions, which could result in a sale or an initial public offering (IPO), come as owners Bain Capital and Cinven evaluate future options for the business.

Sources cited by Welt suggest a potential IPO could take place as early as October 2025 if a private sale does not materialise. A Stada spokesperson confirmed that all options for the company’s future ownership remain under consideration, including both an IPO and a sale.

Bain Capital and Cinven acquired Stada in 2017 in a landmark €5.3bn deal. Since then, the company has focused on expanding its portfolio of generic drugs and consumer healthcare products. Stada reported a 5% increase in first-quarter operating earnings (adjusted for currency effects) to €245m ($279m), driven by growth in specialty pharmaceuticals.

The discussions reflect growing interest in European healthcare assets, as private equity firms seek to deploy capital in the sector amid persistent market volatility and a challenging IPO environment.

Source: Reuters

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com. 

Can`t stop reading? Read more.